SAN

73.32

+0.23%↑

SRT3

211

-2.34%↓

ORNBV.FI

-1.42%↓

PHMA

96.4

+0.84%↑

DRW3

85.3

-2.51%↓

SAN

73.32

+0.23%↑

SRT3

211

-2.34%↓

ORNBV.FI

-1.42%↓

PHMA

96.4

+0.84%↑

DRW3

85.3

-2.51%↓

SAN

73.32

+0.23%↑

SRT3

211

-2.34%↓

ORNBV.FI

-1.42%↓

PHMA

96.4

+0.84%↑

DRW3

85.3

-2.51%↓

SAN

73.32

+0.23%↑

SRT3

211

-2.34%↓

ORNBV.FI

-1.42%↓

PHMA

96.4

+0.84%↑

DRW3

85.3

-2.51%↓

SAN

73.32

+0.23%↑

SRT3

211

-2.34%↓

ORNBV.FI

-1.42%↓

PHMA

96.4

+0.84%↑

DRW3

85.3

-2.51%↓

Kodu・Aktsiate loetelu・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Suletud

SektorTervishoid

61.05 -23.26

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

79.55

Põhinäitajad
By Trading Economics
Sissetulek	-33M 43M
Müük	7.9M 218M
P/E Sektori keskmine	33.502 49.8
Aktsiakasum	0.834
Kasumimarginaal	19.539
Töötajad	1,950
EBITDA	-21M 63M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+34.06% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	23. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	84M 4.1B
Eelmine avamishind	84.31
Eelmine sulgemishind	61.05

Uudiste sentiment

By Acuity

50%

175 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

51.1 / N/A Toetus ja vastupanu

Laboratorios Farmaceuticos Rovi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. mai 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11. mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11. mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11. mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11. mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11. mai 2026, 22:32 UTC

Tulu

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11. mai 2026, 22:02 UTC

Market Talk

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11. mai 2026, 21:49 UTC

Tulu

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11. mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11. mai 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11. mai 2026, 21:23 UTC

Omandamised, ülevõtmised, äriostud

CSG Systems Sale to NEC Gets CFIUS Clearance

11. mai 2026, 21:12 UTC

Tulu

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11. mai 2026, 21:12 UTC

Tulu

Ovintiv 1Q Loss/Shr $2.35 >OVV

11. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11. mai 2026, 20:44 UTC

Tulu

Steris: Board Approves New $1B Shr Repurchase Program >STE

11. mai 2026, 20:43 UTC

Tulu

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11. mai 2026, 20:32 UTC

Tulu

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11. mai 2026, 20:32 UTC

Tulu

CleanSpark 2Q Rev $136.4M >CLSK

11. mai 2026, 20:30 UTC

Tulu

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Cont Ops EPS $2.24 >STE

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Rev $1.6B >STE

11. mai 2026, 20:30 UTC

Tulu

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Adj EPS $2.83 >STE

11. mai 2026, 20:22 UTC

Kuumad aktsiad

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11. mai 2026, 19:37 UTC

Tulu

More Bad News at KKR's Private Credit Fund -- Barrons.com

11. mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Laboratorios Farmaceuticos Rovi SA Prognoos

Hinnasiht

By TipRanks

34.06% tõus

12 kuu keskmine prognoos

Keskmine 83.25 EUR 34.06%

Kõrge 83.5 EUR

Madal 83 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

51.1 / N/AToetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

175 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.